Carlos S. Moreno, Ph.D.



Associate Professor


Department of Pathology & Laboratory Medicine

Department of Biomedical Informatics

Emory University School of Medicine

Member, Winship Cancer Institute



Publications on PubMed

Updated Citations on Google Scholar

Research Highlights

Op Ed Pieces, Blog Posts, and Public Scholarship

Twitter @Carlos_S_Moreno

CTD2 Dashboard





My main research interests are in translational cancer bioinformatics and systems biology, to identify diagnostic markers for more effective and personalized therapies, to identify new potential therapeutic targets, and to better understand the biology of tumor progression. My research has focused on the dissection of the perturbed transcriptional networks in prostate, brain, breast, and ovarian cancers using DNA microarrays and next generation sequencing. My lab has identified several genes that are strongly correlated with prostate cancer progression, including two developmental transcription factors, HOXC6 and SOX4. We are also developing mRNA and microRNA biomarkers of recurrence in prostate cancer. My lab analyzes genome-wide expression profiles, transcriptional networks, ChIP-chip and ChIP-seq studies, biological pathways, and evolutionarily conserved transcription factor binding sites to dissect cancer-related transcriptional networks and identify new drug targets and biomarkers. We are heavily involved in analysis of data from The Cancer Genome Atlas project to identify potential drug targets as part of the Cancer Target Discovery and Development (CTD²) Network at NCI.


      Emory University                                                       Atlanta, GA
                     Ph.D. in Genetics and Molecular Biology (1992-98)

      Massachusetts Institute Of Technology                       Cambridge, MA
                     M.S. in Aerospace Engineering (1986-88)

      Massachusetts Institute Of Technology                       Cambridge, MA
                     B.S. in Aerospace Engineering (1982-86)


1998-2001  Postdoctoral Fellow in the laboratory of Dr. David C. Pallas, Biochemistry Department, Emory University School of Medicine.  Identified and analyzed the striatin/SG2NA family of regulatory subunits for Protein Phosphatase 2A (PP2A) and their role in cell cycle regulation.  Discovered that the mouse homolog of MOB1, a yeast protein essential for initiation of cytokinesis and maintenance of ploidy, binds to striatin/PP2A and SG2NA/PP2A complexes and is a PP2A substrate.  Developed and applied quality threshold clustering algorithms for analysis of gene expression profiles of renal carcinomas.



1992-1998  Studied the regulation of transcription of human Major Histocompatibility Complex (MHC) class II genes.  Cloned and characterized factors that bind to the X box of MHC class II promoters.  One of these factors, X2BP, was purified and shown to be identical to the cAMP response element binding protein (CREB).  The other factor, RFX, was shown to be a multimeric phosphoprotein, and a novel subunit (RFX-B) was identified by metabolic labeling and immunoprecipitation analysis.



1990-1992 Aerospace Engineer, CS Draper Laboratory, Cambridge, MA.  Developed changes to the Space Shuttle Navigation Flight Software for incorporation of Global Positioning System (GPS) navigation data.   Enhanced and developed computer simulations of Space Shuttle Re-Entry.

1988-1990 Aerospace Engineer, NASA Jet Propulsion Laboratory, Pasadena, CA. Performed technology development research for the Mars Rover/Pathfinder Mission.  Researched remote sample acquisition, robotic end effector technology, semi-autonomous navigation systems, and lander/rover vehicle design.




Recent Selected Publications:

2017. KL Pellegrini, MG Sanda, D Patil, Q Long, N Erho, M Takhar, K Yousefi, M Santiago-Jimenez, E Davicioni, EA Klein, RB Jenkins, RJ Karnes, and CS Moreno, Evaluation of a 24-Gene Signature for Prognosis of Metastatic Events and Prostate Cancer-Specific Mortality, British Journal of Urology. doi: 10.1111/bju.13779.     PubMed

2017. S Harati, LAD Cooper, JD Moran, Y Du, AA Ivanov, MA Johns, FR Khuri, H Fu, and CS Moreno, MEDICI: Mining Essentiality Data to Identify Critical Interactions for Cancer Drug Target Discovery and Development, PLoS ONE, 12:e0170339.     PubMed

2017. Z Li, AA Ivanov, R Su, V Gonzalez-Pecchi, Q Qi, S Liu, P Webber, E McMillan, L Rusnak, C Pham, X Chen, X Mo, B Revennaugh, W Zhou, A Marcus, S Harati, X Chen, MA Johns, MA White, CS Moreno, LA Cooper, Y Du, FR Khuri, H Fu, The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategies, Nature Communications, 8:14356.     PubMed

2016. B Bilir, AO Osunkoya, WG Wiles IV, S Sannigrahi, V Lefebvre, D Metzger, DD Spyropoulos, WD Martin, and CS Moreno. SOX4 is essential for prostate tumorigenesis initiated by PTEN ablation. Cancer Research, 76:1112-1121.     PubMed

2015. KL Pellegrini, MG Sanda, and CS Moreno. RNA biomarkers to facilitate the identification of aggressive prostate cancer. Mol Aspects Med., 45:37-46.     PubMed

2015. DA Hughes, W Kircher, Z He, S Guo, GL Fairbrother, CS Moreno, P Khaitovich, and M Stoneking. Evaluating intra- and inter-individual variation in the human placental transcriptome. Genome Biology, 16:54.     PubMed

2015. F Lian, NV Sharma, JD Moran, and CS Moreno, The biology of castration-resistant prostate cancer. Current Problems in Cancer, 39(1):17-28.     PubMed

2014. WG Wiles 4th, Z Mou, Y DU, AB Long, CD Scharer, B Bilir, DD Spyropoulos, NA Jenkins, NG Copeland, WD Martin, and CS Moreno, Mutation of Murine Sox4 Untranslated Regions Results in Partially Penetrant Perinatal Lethality, In Vivo, 28(5):709-718.     PubMed

2014. G Chen, J Kong, C Tucker-Burden, M Anand, Y Rong, F Rahman, CS Moreno, EG Van Meir, CG Hadjipanayis, and DJ Brat, Human Brat ortholog TRIM3 is a tumor suppressor that regulates asymmetric cell division in glioblastoma, Cancer Research, 74(16):4536-48.     PubMed

2014. Q Long, J Xu, AO Osunkoya, S Sannigrahi, BA Johnson, W Zhou, T Gillespie, JY Park, RK Nam, L Sugar, A Stanimirovic, AK Seth, JA Petros, and CS Moreno, Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence, Cancer Research, 74(12):3228-37.     PubMed

2014. Lee M-Y, CS Moreno, Saavedra HI, The E2F activators signal and maintain centrosome amplification in breast cancer cells, Molecular and Cellular Biology, in press. May 5. [Epub ahead of print]      PubMed

2013. B Bilir, O Kucuk, and CS Moreno, Wnt pathway blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells, Journal of Translational Medicine, 11:280.     PubMed

2013. N Dey, BG Barwick, CS Moreno, M Ordanic-Kodani, P De, W Tang, M Bouzyk, GW Sledge, C Catzavelos, KF Kerstann, G Oprea-Ilies, M Abramovitz, and BR Leyland-Jones, Wnt Signaling in Triple Negative Breast Cancer is Associated with Metastasis, BMC Cancer, 13(1):537.     PubMed

2013. J Kong, LAD Cooper, F Wang, J Gao, G Teodoro, L Scarpace, T Mikkelsen, CS Moreno, JH Saltz, and DJ Brat, Large-scale Microscopic Image Analysis of Oligodendroglioma Component in Glioblastoma Uncovers An Oligodendroglial Molecular Signature, PLoS One, 8(11):e81049. doi: 10.1371     PubMed

2013. WC Rutledge, J Kong, J Gao, DA Gutman, L Cooper, C Appin, Y Park, L Scarpace, T Mikkelsen, ML Cohen, KD Aldape, RE McLendon, NL Lehman, CR Miller, MJ Schniederjan, CW Brennan, CS Moreno, JH Saltz, DJ Brat., Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin Cancer Res., 2013 19(18):4951-60.     PubMed

2013. KE Fisher, Q Yin-Goen, D Alexis, JS Sirintrapun, W Harrison, RB Isett, MR Rossi, CS Moreno, AN Young, and AO Osunkoya, Gene expression profiling of clear cell papillary renal cell carcinoma: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma, Modern Pathology, 2013 Jul 26. doi: 10.1038/modpathol.2013.140. [Epub ahead of print]     PubMed

2012. CJ Phillip, CK Giardina, B Bilir, DJ Cutler, YH Lai, O Kucuk, and CS Moreno, Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells. BMC Cancer, 12:145.     PubMed

2012. LA Cooper, DA Gutman, C Chisolm, C Appin, J Kong, Y Rong, T Kurc, EG Van Meir, JH Saltz, CS Moreno, DJ Brat, The Tumor Microenvironment Strongly Impacts Master Transcriptional Regulators and Gene Expression Class of Glioblastoma. American Journal of Pathology, 180(5):2108-19.     PubMed

2012. Cooper LA, Kong J, Gutman DA, Wang F, Gao J, Appin C, Cholleti S, Pan T, Sharma A, Scarpace L, Mikkelsen T, Kurc T, CS Moreno, Brat DJ, Saltz JH Integrated morphologic analysis for the identification and characterization of disease subtypes. J Am Med Inform Assoc, 19(2):317-23.     PubMed

2011. Y-H Lai, J Cheng, D Cheng, ME Feasel, KD Beste, J Peng, A Nusrat and CS Moreno, SOX4 interacts with Plakoglobin in a Wnt3a-dependent manner in prostate cancer cells BMC Cell Biology, 12:50.     PubMed

2011. M Abramovitz, BG Barwick, S Willis, B Young, C Catzavelos, Z Li, M Kodani, W Tang, M Bouzyk, CS Moreno, and B Leyland-Jones, Molecular characterisation of formalin-fixed paraffin-embedded (FFPE) breast tumour specimens using a custom 512-gene breast cancer bead array-based platform. Br J Cancer., 105(10):1574-81.    PubMed

2011. S Girirajan, Z Brkanac, BP Coe, C Baker, L Vives, TH Vu, N Shafer, R Bernier, GB Ferrero, M Silengo, ST Warren, CS Moreno, M Fichera, C Romano, WH Raskind, and E Eichler, Relative burden of large CNVs on a range of neurodevelopmental phenotypes, PLoS Genetics, 7(11): e1002334.     PubMed

2011. Q Long, BA Johnson, AO Osunkoya, Y-H Lai, W Zhou, M Abramovitz, M Xia, M Bouzyk, R Nam, L Sugar, A Stanimirovic, BR Leyland-Jones, AK Seth, JA Petros, CS Moreno, Protein-coding and MicroRNA Biomarkers of Recurrence of Prostate Cancer Following Radical Prostatectomy, American Journal of Pathology, 179(1):46-54.     PubMed     PDF   

2011. Q Long, M Chung, CS Moreno, and BA Johnson, Risk Prediction For Prostate Cancer Recurrence Through Regularized Estimation With Simultaneous Adjustment For Nonlinear Clinical Effects, Annals of Applied Statistics, 5(3): 2003-2023.      PubMed  

2011. A Gordanpour, A Stanimirovic, RK Nam, CS Moreno, C Sherman, L Sugar, and A Seth, miR-221 is Down-regulated in TMPRSS2:ERG Fusion-positive Prostate Cancer, Anticancer Research, 31(2):403-10.    PubMed  

2010. LA Cooper, DA Gutman, Q Long, BA Johnson, SR Cholleti, T Kurc, JH Saltz, DJ Brat, CS Moreno, The Proneural Molecular Signature is Enriched in Oligodendrogliomas and Predicts Improved Survival among Diffuse Gliomas, PLoS One, Sep 3;5(9). pii: e12548.    PubMed  

2010. MW Coolen, C Stirzaker, JZ Song, AL Statham, Z Kassir, CS Moreno, AN Young, V Varma, TP Speed, M Cowley, P Lacaze, W Kaplan, MD Robinson, and SJ Clark. Consolidation of the cancer genome into domains of repressive chromatin by long range epigenetic silencing (LRES), Nature Cell Biology, 12(3):235-46.    PubMed  

2010. BG Barwick, M Abramovitz, M Bouzyk, M Ordanic-Kodani, CS Moreno, R Nam, W Tang, A Seth, BR Leyland-Jones, Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts, British Journal of Cancer, 102(3):570-6.    PubMed   Journal   

2010. CS Moreno. The SOX4 and HOXC6 Transcriptional Networks in Prostate Cancer Progression: Crosstalk with the Wnt, Notch, and PI3K Pathways, American Journal of Pathology, 176(2):518-27.    PubMed   Journal   

2009. CD Scharer, CD McCabe, M Ali-Seyed, MF Berger, ML Bulyk, and CS Moreno. Genome-wide Promoter Analysis of the SOX4 Transcriptional Network in Prostate Cancer Cells, Cancer Research, 69:709-717.    PDF    Journal    PubMed

Curriculum Vitae





Department of Pathology & Laboratory Medicine
Emory University School of Medicine
Whitehead Research Building, Room 105J
615 Michael St.
Atlanta, GA 30322


404-712-2809 (office)
404-712-2808 (lab)


cmoreno at